Rxbio, Inc.
CAGE Code: 4CJP9
NCAGE Code: 4CJP9
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 185698334
Summary
Rxbio, Inc. is an Active Commercial Supplier with the Cage Code 4CJP9 and is tracked by Dun & Bradstreet under DUNS Number 185698334..
Address
1325 Sunset Dr
Johnson City TN 37604-3619
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Chenango Contracting, Inc. Vibiest Consulting Llc Kz Construction, Inc Material Systems Inc Mountain View Specialty Inc Roydent Dental Products Extreme Excavation, Llc Enhanced Systems Consulting, Inc. Del Ray Labs Inc Premier Plumbing Llc Eac Industries Inc Sheraton Plaza Hotel Ventana East Corp Azon Corp R And K Associates Inc Holiday Inn Gordons Inc Tools R Us Ltd Morris-Baker Funeral Home Inc Columbus Electric Mfg Co
Frequently Asked Questions (FAQ) for CAGE 4CJP9
- What is CAGE Code 4CJP9?
- 4CJP9 is the unique identifier used by NATO Organizations to reference the physical entity known as Rxbio, Inc. located at 1325 Sunset Dr, Johnson City TN 37604-3619, United States.
- Who is CAGE Code 4CJP9?
- 4CJP9 refers to Rxbio, Inc. located at 1325 Sunset Dr, Johnson City TN 37604-3619, United States.
- Where is CAGE Code 4CJP9 Located?
- CAGE Code 4CJP9 is located in Johnson City, TN, USA.
Contracting History for CAGE 4CJP9 Most Recent 25 Records
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 6 Dec 2022
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,591,511.92
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 5 Apr 2022
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,573,082.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 14 Jan 2022
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,573,082.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 14 Sep 2021
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,573,082.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 22 Jun 2022
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,591,511.92
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 26 May 2022
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,591,511.92
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- 6 Aug 2021
- Ind-Enabling Development Of Rx100 As A Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,573,082.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00052
- Eo14042 Cell Epitope Discovery And Mechanisms Of Antibody Protection
- 30 Nov 2021
- Eo14042 Cell Epitope Discovery And Mechanisms Of Antibody Protection
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,573,082.00
- Department Of Health And Human Services (Hhs)